

Pharmacology of Multiple Sclerosis Current Therapies and Emerging Trends

Venumbaka Sravya Sree ^{1*}, Kongi Kavyasudha M. Pharm ², Dr. Yadala Prapurna Chandra M. Pharm, Ph.D.³

1 Pursuing Bachelor of Pharmacy at Rathnam Institute of Pharmacy, Pidathapolur, Nellore, INDIA.*

2Faculty- Associate Professor of Pharmacology, Rathnam Institute of Pharmacy, Pidathapolur, Nellore.

M.Pharm. in Pharmacology, Sree Venkateshwara University, Tirupati, INDIA.

3.Principal of Rathnam Institute of Pharmacy, Pidathapolur, Nellore. Ph.D. in Pharmacology, KLE University, Belgaum, INDIA.

Date of Submission: 15-09-2025

Date of Acceptance: 25-09-2025

ABSTRACT:

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system that leads to inflammation, demyelination, and progressive neurodegeneration. It is a major cause of disability among young adults, especially women, and is associated with a wide range of clinical symptoms, including optic neuritis, sensory and motor deficits, fatigue, bladder dysfunction, and cognitive impairment. The etiology of MS is multifactorial, with genetic predisposition such as HLA-DRB1*15:01, and environmental factors like Epstein-Barr virus infection, vitamin D deficiency, obesity, and smoking playing important roles in disease onset and progression. The pathophysiology involves an abnormal immune response in which autoreactive T cells and B cells cross the blood-brain barrier, triggering neuroinflammation, myelin loss, and axonal injury. Over time, chronic activation of microglia and mitochondrial dysfunction further contribute to neuronal degeneration and permanent disability. This understanding has driven the development of disease-modifying therapies (DMTs), which aim to reduce relapses, delay progression, and improve quality of life. Traditional injectable agents such as interferons and glatiramer acetate have been widely used, while newer oral drugs, including fingolimod, dimethyl fumarate, and cladribine, as well as monoclonal antibodies like ocrelizumab and natalizumab, provide enhanced efficacy. Recent research focuses on emerging strategies such as remyelination therapies, Bruton's tyrosine kinase inhibitors, stem cell transplantation, and microbiome modulation. Although no curative treatment exists, advances in pharmacology and personalized medicine continue to transform MS management, offering new hope for patients worldwide.

Keywords: Multiple sclerosis, autoimmunity, demyelination, disease-modifying therapies, monoclonal antibodies, remyelination, emerging therapies.

I. INTRODUCTION:

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS), characterized by inflammation, demyelination, and neurodegeneration. The disease primarily affects young adults between the ages of 20 and 40 years and is more common in women than men, with a female-to-male ratio of approximately 3:1 (1). MS is recognized as one of the leading non-traumatic causes of neurological disability in young adults worldwide (2). The global prevalence of MS is estimated to be over 2.8 million people, and epidemiological studies suggest that the incidence is rising due to improved diagnostic tools and environmental influences (3).



Fig. 1 Multiple sclerosis

The exact cause of MS is not fully understood, but it is believed to be the result of a complex interaction between genetic predisposition and environmental triggers. Genetic studies have identified strong associations with the HLA-DRB1*15:01 allele, while environmental risk

factors include Epstein–Barr virus (EBV) infection, vitamin D deficiency, smoking, and adolescent obesity (4). These factors may initiate an abnormal immune response in genetically susceptible individuals, leading to autoreactive T cells crossing the blood–brain barrier (BBB) and attacking myelin antigens (5). Clinically, MS presents in different forms based on its disease course. The most common type is relapsing-remitting MS (RRMS), characterized by episodic relapses followed by partial or complete recovery. Over time, many patients with RRMS transition to secondary progressive MS (SPMS), where neurological disability accumulates independent of relapses. In contrast, primary progressive MS (PPMS) shows a steady progression of disability from onset without distinct relapses (6). These subtypes highlight the heterogeneity of the disease and its complex underlying mechanisms.

MULTIPLE SCLEROSIS




Fig. 2 Difference between healthy and affected neurons

The diagnosis of MS relies on the demonstration of lesions disseminated in magnetic resonance imaging (MRI), along with cerebrospinal fluid (CSF) findings such as the presence of oligoclonal bands (7). Clinical symptoms vary depending on the location of demyelinating lesions and may include optic neuritis, motor and sensory disturbances, balance problems, fatigue, and cognitive impairment. Up to 70% of patients with MS experience some degree of cognitive dysfunction, significantly affecting quality of life (8). Despite significant advancements in understanding MS, it remains an incurable disease. However, the introduction of disease-modifying therapies (DMTs) has revolutionized its management by reducing relapse rates, slowing

progression, and improving patient outcomes. Ongoing research into novel therapies, including remyelination and neuroprotection strategies, continues to provide hope for a potential cure in the future.

PATHOPHYSIOLOGY OF MULTIPLE SCLEROSIS:

1. IMMUNE SYSTEM ACTIVATION

Multiple sclerosis (MS) develops when the immune system becomes abnormally activated against components of the central nervous system (CNS). Autoreactive CD4+ T helper cells (Th1 and Th17) cross the blood–brain barrier (BBB) and release pro-inflammatory cytokines, including interferon-gamma (IFN- γ), interleukin-17 (IL-17),

and tumor necrosis factor-alpha (TNF- α), which recruit other immune cells (9). CD8+ cytotoxic T cells also directly damage oligodendrocytes and axons, aggravating CNS inflammation (10).




Fig. 3 Activation of the immune system

2. Role of B Cells and Antibodies

Earlier models focused mainly on T cells, but current research highlights the importance of B cells. B cells produce autoantibodies against myelin proteins, secrete inflammatory cytokines, and act as antigen-presenting cells to T lymphocytes (11). The discovery of oligoclonal bands in cerebrospinal fluid (CSF) remains one of the strongest pieces of evidence of B cell involvement (12). Therapies targeting B cells, such as anti-CD20 monoclonal antibodies, confirm their central role in MS pathology (13).

Multiple sclerosis/EAE




Fig. 3 Path of B cells and antibodies

3. Blood–Brain Barrier (BBB) Breakdown

The BBB normally protects the CNS from peripheral immune cell entry. In MS, inflammatory mediators and matrix metalloproteinases disrupt BBB integrity, allowing autoreactive lymphocytes to infiltrate the brain and spinal cord (14). Adhesion molecules such as very late antigen-4 (VLA-4) and integrins further promote immune cell migration across the barrier, initiating demyelinating lesions (15)

Immune Activation & BBB Breakdown




Fig. 4 BBB Breakdown

4. Demyelination and Axonal Loss

Once inside the CNS, activated immune cells target myelin, the protective sheath around axons. Myelin basic protein (MBP) and proteolipid protein (PLP) become primary antigenic targets, leading to focal demyelination (16). Microglial

cells and macrophages release reactive oxygen species (ROS) and nitric oxide, amplifying axonal injury (17). Chronic demyelination results in impaired nerve conduction and irreversible neurodegeneration (18).

Demyelination of Neuron




Fig. 5 Neuron demyelination

5. Neurodegeneration and Progressive MS

In progressive stages of MS, neurodegeneration predominates over inflammation. Chronic activation of microglia, mitochondrial dysfunction, and iron accumulation in brain tissue contribute to axonal degeneration (19). This process is less responsive to conventional anti-inflammatory therapies, explaining why progressive MS remains more difficult to treat (20).




Fig. 6 Neurodegeneration in the treatment of MS

DRUGS USED IN MULTIPLE SCLEROSIS (MS):

Drug Class	Examples	Route	Mechanism of action	Clinical use
Interferon based therapies(21)	Interferon β -1a Interferon β -1b	Injection (SC/IM)	Modulates immune response, reduces T-cell activation, and decreases pro-inflammatory cytokines	RRMS
			Mimics myelin	

Synthetic polypeptide (22)	Glatiramer acetate	Injection (SC)	basic protein, induces Th2 cells, anti-inflammatory effect	RRMS, CIS
Oral Sphingosine-1-phosphate(S1P) receptor modulators (23)	Fingolimod,sipono mod, Ozanimod	Oral	Traps lymphocytes in lymph nodes, preventing CNS infiltration	RRMS SPMS
Monoclonal antibodies (24)	NatalizumabOcerelimumabAlemtuzumab	IV	Blocks immune cell entry across the BBB, depletes B cells	RRMS PPMS
Oral immunomodulators (25)	Dimethyl fumarate, TeriflunomideCladribine	Oral	Anti-inflammatory and cytotoxic effects; Reduces oxidative stress	RRMS Active SPMS

Table 1: Drugs used in the treatment of MS

ADVERSE EFFECTS OF DISEASE-MODIFYING THERAPIES IN MS:

1. Interferon Beta

Interferon beta preparations commonly cause flu-like symptoms, injection site reactions, and elevated liver enzymes, which may affect patient adherence [26].

2. Glatiramer Acetate

Glatiramer acetate may lead to injection site reactions, chest pain, and transient systemic reactions, including rare anaphylaxis [27].

3. Fingolimod

Fingolimod can cause bradycardia, macular edema, and elevated liver enzymes, requiring monitoring during therapy [28].

4. Teriflunomide

Teriflunomide is associated with hepatotoxicity, teratogenicity, and gastrointestinal disturbances, necessitating liver function monitoring and contraception [29].

5. Natalizumab

Natalizumab carries a risk of progressive multifocal leukoencephalopathy (PML), especially

in patients with anti-JCV antibodies or prolonged use [30].

6. Ocrelizumab

Ocrelizumab may cause infusion reactions, increased risk of infections, and a possible elevated risk of malignancies [31].

7. Alemtuzumab

Alemtuzumab treatment may lead to autoimmune disorders, thyroid dysfunction, and infections, requiring careful monitoring [32].

8. Cladribine

Cladribine can result in lymphopenia, hematologic abnormalities, and infections, making patient selection and follow-up crucial [33].

COGNITIVE IMPAIRMENT IN MS:

Cognitive impairment affects 40–70% of MS patients, mainly targeting attention, processing speed, memory, and executive functions [34]. These deficits interfere with daily life, work, and social interactions. Cognitive decline can be subtle at first but may worsen with disease progression. Early detection through neuropsychological tests can help in planning interventions. Additionally, neuroimaging techniques like MRI and functional imaging provide insight into structural and

functional brain changes associated with cognitive impairment [35]. Lifestyle interventions, cognitive rehabilitation, and some disease-modifying therapies (DMTs) have shown potential in stabilizing cognition. Addressing comorbidities, like depression and fatigue, is also crucial to improve cognitive outcomes [36].




Fig. 7 Cognitive management in MS

FATIGUE AND QUALITY OF LIFE:

Fatigue is one of the most disabling symptoms of MS, affecting up to 80% of patients [37]. It is multifactorial, involving immune dysregulation, neurological damage, sleep disturbances, and medication side effects. Fatigue significantly reduces quality of life and may lead to social isolation and depression. Interventions include energy management strategies, regular exercise, pharmacological treatments like amantadine, and addressing sleep disorders. Measuring fatigue with standardized scales helps clinicians monitor and optimize treatment effectiveness [38].




Fig. 8:Effect of Fatigue in MS

VISUAL DISTURBANCES:

Neuritis and other visual problems are common in MS [39]. Patients often experience blurred vision, color desaturation, and eye pain, especially during acute relapses. MRI can detect lesions in the optic nerve and visual pathways, helping confirm the diagnosis. Timely corticosteroid therapy may reduce the duration of Optic visual symptoms. Rehabilitation strategies, including vision therapy and assistive devices, improve daily functioning.




Fig. 9 Visual problems in MS

DYSFUNCTION MOTOR AND SPASTICITY:

Motor dysfunction, including muscle weakness, spasticity, and impaired coordination, is prevalent in MS [40]. These symptoms affect mobility, increase fall risk, and reduce independence. Treatments include physical therapy, stretching exercises, muscle relaxants like baclofen, and assistive devices. Early interventions improve balance and functional mobility.




Fig. 10 Motor dysfunction in MS

MOOD DISORDERS AND PSYCHOLOGICAL IMPACT MS:

Patients are at higher risk of depression, anxiety, and emotional lability [41]. Chronic

illness, uncertainty about prognosis, and neurological changes contribute to psychological stress. Early psychological support, counseling, and pharmacological management improve coping skills and quality of life. Cognitive-behavioral therapy (CBT) has demonstrated efficacy in reducing depressive symptoms.




Fig11 Mood disorders in MS

SLEEP DISTURBANCES IN MULTIPLE SCLEROSIS:

Sleep disorders, including insomnia, restless legs syndrome, and sleep apnea, are highly prevalent in MS patients, affecting up to 50% of individuals [42]. Poor sleep exacerbates fatigue, cognitive impairment, and mood disorders, significantly reducing quality of life. Contributing factors include neuropathic pain, nocturia, muscle spasms, and medication side effects. Management strategies involve sleep hygiene education, pharmacological therapy, and treatment of underlying comorbidities. Cognitive behavioral therapy for insomnia (CBT-I) has also shown effectiveness in improving sleep quality in MS patients. Monitoring sleep patterns with actigraphy or polysomnography can help tailor interventions to individual needs.

PAIN MANAGEMENT IN MS:

Pain is a common and often under-recognized symptom in MS, including neuropathic pain, spasticity-related pain, and musculoskeletal discomfort [43].¹ Neuropathic pain arises from demyelination and aberrant nerve signaling,

presenting as burning, stabbing, or electric-shock-like sensations. Management includes pharmacological interventions such as anticonvulsants (e.g., gabapentin), antidepressants (e.g., duloxetine), and non-pharmacological therapies like physiotherapy, massage, and mindfulness-based approaches. Regular pain assessment is critical to improving patient quality of life and functional ability.

BLADDER DYSFUNCTION AND URINARY SYMPTOMS:

Bladder dysfunction affects approximately 80% of MS patients, presenting as urgency, frequency, incontinence, or retention [44]. Neurogenic bladder results from lesions affecting the spinal cord or brain regions controlling micturition. Management strategies include anticholinergic drugs, intermittent catheterization, pelvic floor exercises, and behavioral interventions. Early identification and treatment reduce urinary tract infections, kidney complications, and social embarrassment, enhancing patient confidence and daily functioning.




Fig:12 Bladder dysfunctions

SEXUAL DYSFUNCTION IN MS:

Sexual dysfunction is frequently reported in MS patients, including erectile dysfunction, reduced libido, vaginal dryness, and anorgasmia [45]. These problems are caused by neurological lesions, fatigue, depression, and medication side effects. Open communication with healthcare providers, sexual counseling, pharmacological therapy, and lifestyle modifications can improve sexual health. Addressing sexual dysfunction enhances relationship satisfaction and overall quality of life.

A type of sexual disorder in women suffering from MS	Percentage distribution
Desire disorders	57.7%
Hydration disorders	48.4%
Genital disorders	47.3%
Cognitive disorders	45.2%
Augasmic disorders	39.8%

Fig:13 Sexual disorders in MS

EMERGING THERAPIES AND FUTURE DIRECTIONS:

Recent advances in MS therapy focus on remyelination, neuroprotection, and personalized medicine [46]. Novel agents, including BTK inhibitors, stem cell therapy, and monoclonal antibodies, show promise in reducing disease progression and repairing neurological damage. Research also emphasizes biomarkers for early detection, treatment response, and relapse prediction. These emerging therapies may transform MS management by improving patient outcomes and quality of life, offering hope for more effective, individualized treatment strategies.




Fig:14 Stem cell therapy in MS treatment

III. CONCLUSION:

Multiple sclerosis (MS) is a complex, chronic autoimmune disorder affecting the central nervous system. The disease manifests with a wide range of neurological, cognitive, and physical symptoms, making management highly individualized [47]. Current disease-modifying therapies (DMTs) have significantly improved relapse rates and delayed progression, yet challenges remain in managing adverse effects, fatigue, cognitive impairment, and quality-of-life issues [48]. Recent advances in biomarker research, neuroimaging techniques, and precision medicine offer promising avenues for early diagnosis and personalized treatment strategies [49]. Additionally, rehabilitation approaches addressing cognition, mobility, pain, sleep, and mood play a crucial role in holistic patient care. Interdisciplinary management involving neurologists, physiotherapists, psychologists, and nurses enhances patient outcomes [50]. Emerging therapies, including remyelination agents, neuroprotective drugs, and stem cell-based interventions, hold potential for slowing disease progression and promoting neural repair [51]. Ongoing research, clinical trials, and patient-centered care strategies are vital to further improve treatment efficacy, minimize side effects, and enhance the overall quality of life for MS patients. A comprehensive understanding of MS, continuous monitoring, and innovative treatment approaches can provide hope for patients, families, and caregivers, shaping a future with better clinical

II.

outcomes and improved daily living experiences [47–51]



Fig. 15 Urge to know about MS

REFERENCES:

- [1]. Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018). Multiple sclerosis. *New England Journal of Medicine*, 378(2), 169–180. <https://doi.org/10.1056/NEJMr1401483>
- [2]. Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018). Multiple sclerosis. *Nature Reviews Disease Primers*, 4(1), 43. <https://doi.org/10.1038/s41572-018-0041-4>

- [3]. Wallin, M. T., Culpepper, W. J., Nichols, E., Bhutta, Z. A., Gebrehiwot, T. T., Hay, S. I., ... & Feigin, V. L. (2019). Global, regional, and national burden of multiple sclerosis 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology*, 18(3), 269–285. [https://doi.org/10.1016/S1474-4422\(18\)30443-5](https://doi.org/10.1016/S1474-4422(18)30443-5)
- [4]. Belbasis, L., Bellou, V., Evangelou, E., Tzoulaki, I., & Ioannidis, J. P. (2015). Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and meta-analyses. *The Lancet Neurology*, 14(3), 263–273. [https://doi.org/10.1016/S1474-4422\(14\)70267-4](https://doi.org/10.1016/S1474-4422(14)70267-4)
- [5]. Hauser, S. L., & Cree, B. A. C. (2020). Treatment of multiple sclerosis: A review. *American Journal of Medicine*, 133(12), 1380–1390. <https://doi.org/10.1016/j.amjmed.2020.05.049>
- [6]. Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., ... & Polman, C. H. (2014). Defining the clinical course of multiple sclerosis: The 2013 revisions. *Neurology*, 83(3), 278–286. <https://doi.org/10.1212/WNL.0000000000000560>
- [7]. Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., ... & Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *The Lancet Neurology*, 17(2), 162–173. [https://doi.org/10.1016/S1474-4422\(17\)30470-2](https://doi.org/10.1016/S1474-4422(17)30470-2)
- [8]. Chiaravalloti, N. D., & DeLuca, J. (2008). Cognitive impairment in multiple sclerosis. *The Lancet Neurology*, 7(12), 1139–1151. [https://doi.org/10.1016/S1474-4422\(08\)70259-X](https://doi.org/10.1016/S1474-4422(08)70259-X)
- [9]. Korn, T., & Kallies, A. (2017). T cell responses in the central nervous system. *Nature Reviews Immunology*, 17(3), 179–194. <https://doi.org/10.1038/nri.2016.144>
- [10]. Sospedra, M., & Martin, R. (2016). Immunology of multiple sclerosis. *Annual Review of Immunology*, 34, 299–329. <https://doi.org/10.1146/annurev-immunol-032414-112020>
- [11]. Li, R., Patterson, K. R., & Bar-Or, A. (2018). Reassessing B cell contributions in multiple sclerosis. *Nature Immunology*, 19(7), 696–707.
- [12]. Dobson, R., & Giovannoni, G. (2019). Multiple sclerosis – a review. *European Journal of Neurology*, 26(1), 27–40. <https://doi.org/10.1111/ene.13819>
- [13]. Hauser, S. L., Bar-Or, A., Cohen, J. A., Comi, G., Correale, J., Coyle, P. K., ... & Cross, A. H. (2017). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. *New England Journal of Medicine*, 376(3), 221–234. <https://doi.org/10.1056/NEJMoa1601277>
- [14]. Minegar, A., & Alexander, J. S. (2003). Blood–brain barrier disruption in multiple sclerosis. *Multiple Sclerosis Journal*, 9(6), 540–549. <https://doi.org/10.1191/1352458503ms965oa>
- [15]. Engelhardt, B., & Ransohoff, R. M. (2012). Capture, crawl, cross: The T cell code to breach the blood–brain barriers. *Trends in Immunology*, 33(12), 579–589. <https://doi.org/10.1016/j.it.2012.07.004>
- [16]. Dendrou, C. A., Fugger, L., & Friese, M. A. (2015). Immunopathology of multiple sclerosis. *Nature Reviews Immunology*, 15(9), 545–558. <https://doi.org/10.1038/nri3871>
- [17]. Mahad, D. H., Trapp, B. D., & Lassmann, H. (2015). Pathological mechanisms in progressive multiple sclerosis. *The Lancet Neurology*, 14(2), 183–193. [https://doi.org/10.1016/S1474-4422\(14\)70256-X](https://doi.org/10.1016/S1474-4422(14)70256-X)
- [18]. Trapp, B. D., & Nave, K. A. (2008). Multiple sclerosis: An immune or neurodegenerative disorder? *Annual Review of Neuroscience*, 31, 247–269. <https://doi.org/10.1146/annurev.neuro.30.051606.094313>
- [19]. Campbell, G. R., & Mahad, D. J. (2018). Mitochondrial dysfunction and axon degeneration in progressive multiple sclerosis. *FEBS Letters*, 592(7), 1113–1121. <https://doi.org/10.1002/1873-3468.12944>
- [20]. Lassmann, H. (2018). Multiple sclerosis pathology. *Cold Spring Harbor Perspectives in Medicine*, 8(3), a028936. <https://doi.org/10.1101/cshperspect.a028936>

- [21]. Goodin, D. S., Reder, A. T., Ebers, G. C., Cutter, G., Kremenchutzky, M., Oger, J., ... & Kappos, L. (2012). Survival in MS: A randomized cohort study of interferon beta-1b. *Neurology*, 78(17), 1315–1322. <https://doi.org/10.1212/WNL.0b013e3182535cfb>
- [22]. Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., ... & Stone, L. A. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. *Neurology*, 45(7), 1268–1276. <https://doi.org/10.1212/WNL.45.7.1268>
- [23]. Kappos, L., Radue, E. W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., ... & Sandbrink, R. (2010). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *New England Journal of Medicine*, 362(5), 387–401. <https://doi.org/10.1056/NEJMoa0909494>
- [24]. Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., ... & Bar-Or, A. (2008). B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *New England Journal of Medicine*, 358(7), 676–688. <https://doi.org/10.1056/NEJMoa0706383>
- [25]. Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., ... & Fox, R. J. (2012). Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *New England Journal of Medicine*, 367(12), 1098–1107. <https://doi.org/10.1056/NEJMoa1114287>
- [26]. Rudick, R. A., Goodkin, D. E., & Jacobs, L. D. (1997). Interferon beta-1a treatment of multiple sclerosis: Clinical effects and adverse events. *Annals of Neurology*, 41(2), 219–227. <https://doi.org/10.1002/ana.410410210>
- [27]. Johnson, K. P., Brooks, B. R., Cohen, J. A., et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting MS. *Neurology*, 45(7), 1268–1276. <https://doi.org/10.1212/WNL.45.7.1268>
- [28]. Calabresi, P. A., Radue, E. W., Goodin, D., et al. (2014). Safety and efficacy of fingolimod in multiple sclerosis. *The Lancet Neurology*, 13(6), 545–556. [https://doi.org/10.1016/S1474-4422\(14\)70031-6](https://doi.org/10.1016/S1474-4422(14)70031-6)
- [29]. O'Connor, P., Wolinsky, J. S., Confavreux, C., et al. (2011). Randomized trial of teriflunomide for relapsing multiple sclerosis. *The New England Journal of Medicine*, 365, 1293–1303. <https://doi.org/10.1056/NEJMoa1014658>
- [30]. Bloomgren, G., Richman, S., Hotermans, C., et al. (2012). Risk of PML in patients receiving natalizumab. *The New England Journal of Medicine*, 366, 1870–1880. <https://doi.org/10.1056/NEJMoa1106968>
- [31]. Hauser, S. L., Bar-Or, A., Cohen, J. A., et al. (2017). Ocrelizumab in relapsing multiple sclerosis. *The New England Journal of Medicine*, 376(3), 221–234. <https://doi.org/10.1056/NEJMoa1601277>
- [32]. Coles, A. J., Twyman, C. L., Arnold, D. L., et al. (2012). Alemtuzumab for patients with relapsing multiple sclerosis: A randomized controlled phase 3 trial. *Lancet*, 380(9856), 1829–1839. [https://doi.org/10.1016/S0140-6736\(12\)61768-1](https://doi.org/10.1016/S0140-6736(12)61768-1)
- [33]. Leist, T. P., & Weissert, R. (2011). Cladribine: Mode of action and implications for treatment of multiple sclerosis. *Clinical Neuropharmacology*, 34(1), 28–35. <https://doi.org/10.1097/WNF.0b013e318203f1f6>
- [34]. Kania, K., et al. (2023). The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: A clinician's review. *Frontiers in Neurology*, 14, 1222574. <https://doi.org/10.3389/fneur.2023.1222574>
- [35]. Mielcarz, J., et al. (2023). Molecular biomarkers and cognitive impairment in multiple sclerosis. *Journal of Clinical Neuroscience*, 99, 1–7. <https://doi.org/10.1016/j.jocn.2023.01.007>
- [36]. Benedict, R. H. B., et al. (2023). Cognitive rehabilitation in multiple sclerosis: Three digital approaches. *Frontiers in Human Neuroscience*, 17, 1130231.

- <https://doi.org/10.3389/fnhum.2023.1130231>
- [37]. Iodice, R., et al. (2023). A review of current rehabilitation practices and their benefits in patients with multiple sclerosis. *Multiple Sclerosis and Related Disorders*, 69, 104460. <https://doi.org/10.1016/j.msard.2022.104460>
- [38]. Krupp, L. B., et al. (2010). Fatigue in multiple sclerosis: Definition, pathophysiology and treatment. *Neurology*, 75(8), 518–526. <https://doi.org/10.1212/WNL.0b013e3181ebddfd>
- [39]. Toosy, A. T., Mason, D. F., & Miller, D. H. (2014). Optic neuritis. *Lancet Neurology*, 13(1), 83–99. [https://doi.org/10.1016/S1474-4422\(13\)70259-X](https://doi.org/10.1016/S1474-4422(13)70259-X)
- [40]. Compston, A., & Coles, A. (2008). Multiple sclerosis. *Lancet*, 372(9648), 1502–1517. [https://doi.org/10.1016/S0140-6736\(08\)61620-7](https://doi.org/10.1016/S0140-6736(08)61620-7)
- [41]. Feinstein, A., et al. (2014). The link between multiple sclerosis and depression. *Nature Reviews Neurology*, 10, 507–517. <https://doi.org/10.1038/nrneurol.2014.135>
- [42]. Veauthier, C., & Paul, F. (2014). Sleep disturbances in multiple sclerosis. *Nature Reviews Neurology*, 10(9), 525–534. <https://doi.org/10.1038/nrneurol.2014.125>
- [43]. O'Connor, A. B., Schwid, S. R., Herrmann, D. N., Markman, J. D., & Dworkin, R. H. (2008). Pain associated with multiple sclerosis: Systematic review and proposed classification. *Pain*, 137(1), 96–111. <https://doi.org/10.1016/j.pain.2007.08.023>
- [44]. Fowler, C. J., Panicker, J. N., Drake, M. J., & Harris, C. A. (2009). Management of urinary disorders in multiple sclerosis. *The Lancet Neurology*, 8(6), 556–567. [https://doi.org/10.1016/S1474-4422\(09\)70072-0](https://doi.org/10.1016/S1474-4422(09)70072-0)
- [45]. Foley, F. W., & Iverson, D. (2015). Sexual dysfunction in multiple sclerosis. *Current Neurology and Neuroscience Reports*, 15, 58. <https://doi.org/10.1007/s11910-015-0585-4>
- [46]. Kamm, C. P., Uitdehaag, B. M. J., & Polman, C. H. (2014). Emerging therapies for multiple sclerosis. *The Lancet*, 383(9916), 1749–1756. [https://doi.org/10.1016/S0140-6736\(13\)62310-2](https://doi.org/10.1016/S0140-6736(13)62310-2)
- [47]. Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018). Multiple sclerosis. *Nature Reviews Disease Primers*, 4, 43. <https://doi.org/10.1038/s41572-018-0041-4>
- [48]. Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., ... Selmaj, K. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. *The New England Journal of Medicine*, 376(3), 209–220. <https://doi.org/10.1056/NEJMoa1606468>
- [49]. Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. *The Lancet*, 391(10130), 1622–1636. [https://doi.org/10.1016/S0140-6736\(18\)30481-1](https://doi.org/10.1016/S0140-6736(18)30481-1)
- [50]. Larochelle, C., & Alvarez, J. I. (2018). Emerging concepts in multiple sclerosis pathophysiology. *Journal of Clinical Investigation*, 128(5), 2201–2210. <https://doi.org/10.1172/JCI97135>
- [51]. Ziemssen, T., & Thomas, K. (2019). Emerging therapies for multiple sclerosis. *Therapeutic Advances in Neurological Disorders*, 12, 1756286419869000. <https://doi.org/10.1177/1756286419869000>